The price of the 20 most prescribed brand-name drugs in the Medicare Part D program increased an average 12% per year between 2012 and 2017, about 10 times more than the average annual rate of inflation, according to a report released this week by Sen. Claire McCaskill (D-MO), ranking member of the Senate Homeland Security and Governmental Affairs Committee. Total price increases for the 20 drugs ranged from 31% to 477% over the five-year period, with six of the drugs more than doubling in price, based on the annual weighted average wholesale acquisition cost. “These findings underscore the need for further investigation by the committee and other policymakers into dramatic price spikes and their impact on health care system costs and financial burdens for the growing U.S. senior population,” the report states.

Related News Articles

Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Blog
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.
Headline
The AHA today responded to a RAND Corporation study that found that certain prices paid to hospitals by private health plans are high relative to Medicare and…